TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA) announced inducement equity awards approved by the Compensation Committee with a Grant Date of November 10, 2025 under Nasdaq Rule 5635(c)(4).
The awards consist of 30,200 restricted stock units granted to seventeen newly hired employees and a 25,000-share stock option granted to one employee. The option exercise price equals $1.19 per share (closing price on the Grant Date), the option term is 10 years, and vesting occurs over four years (25% at the first anniversary, then monthly over 36 months). The RSUs vest in equal annual installments over four years and all awards require continued service through vesting dates.
TELA Bio (NASDAQ: TELA) ha annunciato premi azionari di indizione approvati dal Compensation Committee con una Data di concessione del 10 novembre 2025 ai sensi della Nasdaq Rule 5635(c)(4).
I premi consistono in 30.200 unità azioni vincolate assegnate a diciassette dipendenti recentemente assunti e in una opzione su azioni di 25.000 azioni conferita a un dipendente. Il prezzo di esercizio dell’opzione è pari a $1,19 per azione (prezzo di chiusura nella data di concessione), la durata dell’opzione è 10 anni, e il vesting avviene nel corso di quattro anni (25% al primo anniversario, poi mensilmente sui 36 mesi). Le RSU vestono in rate annuali uguali durante quattro anni e tutti i premi richiedono un servizio continuato fino alle date di vesting.
TELA Bio (NASDAQ: TELA) anunció premios de acciones por inducción aprobados por el Comité de Compensación con una Fecha de Concesión del 10 de noviembre de 2025 bajo la Regla Nasdaq 5635(c)(4).
Los premios consisten en 30.200 unidades de acciones restringidas otorgadas a diecisiete empleados recientemente contratados y en una opción de acciones de 25.000 acciones otorgada a un empleado. El precio de ejercicio de la opción es de $1,19 por acción (precio de cierre en la Fecha de Concesión), el plazo de la opción es de 10 años, y el vesting se produce durante cuatro años (25% al primer aniversario, luego mensualmente durante 36 meses). Las RSU se consolidan en cuotas anuales iguales durante cuatro años y todos los premios requieren un servicio continuo hasta las fechas de vesting.
TELA Bio (NASDAQ: TELA)는 보상위원회가 승인한 유인 주식 보상을 발표했습니다. 부여일은 2025년 11월 10일이며 Nasdaq 규칙 5635(c)(4)에 따른 것입니다.
보상은 17명의 신규 채용 직원에게 부여된 30,200주 제한 주식(unit)과 1명의 직원에게 부여된 25,000주 주식 매입권으로 구성됩니다. 매입권 행사가격은 주당 $1.19이고(부여일 종가), 매입권의 유효기간은 10년이며 베스팅은 4년에 걸쳐 이루어집니다(첫 해에 25%, 이후 36개월 동안 매월 vest). RSU는 4년 동안 매년 같은 비율로 vest되며 모든 보상은 vesting 날짜까지 지속적인 서비스가 필요합니다.
TELA Bio (NASDAQ: TELA) a annoncé des primes d’attribution d’actions approuvées par le Comité de Compensation avec une date d’attribution du 10 novembre 2025 selon la règle Nasdaq 5635(c)(4).
Les primes se composent de 30 200 unités d’actions restreintes attribuées à dix-sept nouveaux employés et d’une option d’achat de 25 000 actions attribuée à un employé. Le prix d’exercice de l’option est à 1,19 USD par action (cours de clôture à la date d’attribution), la durée de l’option est de 10 ans, et la vesting a lieu sur quatre ans (25 % au premier anniversaire, puis mensuellement sur 36 mois). Les RSU vestent en versements annuels égaux sur quatre ans et toutes les primes nécessitent un service continu jusqu’aux dates de vesting.
TELA Bio (NASDAQ: TELA) hat von dem Vergütungsausschuss genehmigte Incentive-Aktienpreise angekündigt, mit einem Zuteilungsdatum vom 10. November 2025 gemäß Nasdaq-Regel 5635(c)(4).
Die Zuteilungen bestehen aus 30.200 Restricted-Stock-Einheiten, die an siebzehn neu eingestellte Mitarbeiter vergeben werden, und einer Aktienoption über 25.000 Aktien, die einem Mitarbeiter gewährt wird. Der Ausübungspreis der Option beträgt 1,19 USD pro Aktie (Schlusskurs am Zuteilungstag), die Optionslaufzeit beträgt 10 Jahre, und der Vesting erfolgt über vier Jahre (25% beim ersten Jahrestag, dann monatlich über 36 Monate). Die RSUs vesten in gleichen jährlichen Raten über vier Jahre, und alle Prämien setzen fortlaufende Dienste bis zu den Vesting-Daten voraus.
TELA Bio (NASDAQ: TELA) أعلنت عن جوائز أسهم التحفيز التي وافق عليها لجنة التعويضات مع تاريخ المنح 10 نوفمبر 2025 وفقًا للقاعدة Nasdaq 5635(c)(4).
تتكون الجوائز من 30,200 وحدة أسهم مقيدة ممنوحة لسبعة عشر موظفاً تم توظيفهم حديثاً و
- None.
- None.
MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The stock options have an exercise price equal to
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
What equity awards did TELA Bio (NASDAQ: TELA) grant on November 10, 2025?
What is the exercise price and term of the TELA Bio stock option granted on November 10, 2025?
How do the TELA Bio stock option vesting terms work for the November 10, 2025 grant?
How do the restricted stock units granted by TELA Bio on November 10, 2025 vest?
Why were these equity awards granted under Nasdaq Rule 5635(c)(4) for TELA Bio?
Do the TELA Bio inducement awards require continued employment to vest?
